TY - JOUR
T1 - BMPs and gene therapy for spinal fusion
T2 - Summary statement
AU - Sandhu, Harvinder S.
AU - Boden, Scott D.
AU - An, Howard
AU - Kang, James
AU - Weinstein, James Neil
PY - 2003/8/1
Y1 - 2003/8/1
N2 - The use of biologic technologies to engender spinal fusion is at various stages of scientific and clinical development. Recombinant human bone morphogenetic protein 2 is now available for clinical use in anterior lumbar intervertebral fusion and has been extensively studied in other spinal fusion applications. Recombinant bone morphogenetic protein 7 is under examination in regulated clinical trials. Gene therapy technologies are in the preclinical stage of development. In time, biologic interventions will continue to capture greater roles in the treatment of spinal disease.
AB - The use of biologic technologies to engender spinal fusion is at various stages of scientific and clinical development. Recombinant human bone morphogenetic protein 2 is now available for clinical use in anterior lumbar intervertebral fusion and has been extensively studied in other spinal fusion applications. Recombinant bone morphogenetic protein 7 is under examination in regulated clinical trials. Gene therapy technologies are in the preclinical stage of development. In time, biologic interventions will continue to capture greater roles in the treatment of spinal disease.
UR - http://www.scopus.com/inward/record.url?scp=0041565461&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0041565461&partnerID=8YFLogxK
U2 - 10.1097/01.brs.0000076903.10966.86
DO - 10.1097/01.brs.0000076903.10966.86
M3 - Short survey
C2 - 12897479
AN - SCOPUS:0041565461
SN - 0362-2436
VL - 28
SP - S85
JO - Spine
JF - Spine
IS - 15 SUPPL.
ER -